Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
SAN DIEGO, Feb. 18, 2016 -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced that George Mahaffey offered his resignation as Chief Executive Officer and Chairman of the Board, effective immediately. The board has formed a committee to oversee day to day operations until a replacement is found. The Company also announced it is evaluating a path forward with a modified formulation of its lead asset LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat. Neothetics will provide a more detailed update in its 10-K and 4Q2015 release.
Neothetics today also reported preliminary fourth quarter 2015 cash and cash equivalents as of December 31, 2015 of approximately $37.7 million.
To receive Neothetics' press releases and other investor information, please go to the Investor Relations page of the company's website at investors.neothetics.com and register for email alerts.
About Neothetics, Inc.
Neothetics is a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market. The lead product candidate, LIPO-202, is for central abdominal bulging due to subcutaneous fat in non-obese subjects, an indication for which there is no FDA-approved drug. If approved, LIPO-202 may be a best-in-class non-surgical, non-ablative procedure and first-in-class injectable formulation for localized fat reduction and body contouring. For more information on Neothetics, please visit www.neothetics.com. Neothetics, LIPO-202, LIPO-102 and the Neothetics logo are trademarks or registered trademarks of Neothetics, Inc. Other names and brands may be claimed as the property of others.
COMPANY CONTACTS: Susan A. Knudson Chief Financial Officer 858-500-7780 [email protected] Fara Berkowitz, R.Ph, Pharm.D Senior Director, Investor Relations and Corporate Strategy 917-460-9307 [email protected]
